Upconverting nanoparticle reporter–based highly sensitive rapid lateral flow immunoassay for hepatitis B virus surface antigen
Autor: | Kim Pettersson, Etvi Juntunen, Navin Khanna, Gaurav Batra, Iida Martiskainen, Teppo Salminen, Dinesh Kumar, Sheikh M. Talha, Tytti Vuorinen, Souvick Chattopadhyay, Karoliina Vuorenpää |
---|---|
Rok vydání: | 2020 |
Předmět: |
Hepatitis B virus
HBsAg Upconverting nanophosphors Point-of-care testing 01 natural sciences Biochemistry Analytical Chemistry 03 medical and health sciences HBV diagnostics Limit of Detection Humans Medicine Point-of-care test Lateral flow 030304 developmental biology Whole blood Immunoassay Detection limit 0303 health sciences Hepatitis B virus surface Antigen Hepatitis B Surface Antigens business.industry 010401 analytical chemistry Blood Screening Equipment Design Hepatitis B Virology 0104 chemical sciences 3. Good health Titer Luminescent Measurements Nanoparticles business Antibodies Immobilized Research Paper Lateral flow immunoassay |
Zdroj: | Analytical and Bioanalytical Chemistry |
ISSN: | 1618-2650 1618-2642 |
Popis: | Detection of hepatitis B Virus surface antigen (HBsAg) is an established method for diagnosing both acute and chronic hepatitis B virus (HBV) infection. In addition to enzyme immunoassays (EIAs), rapid diagnostic tests (RDTs) are available for the detection of HBsAg in resource-poor settings. However, the available RDTs have inadequate sensitivity and therefore are not suitable for diagnosis of patients with low levels of HBsAg and for blood screening. To provide a high-sensitivity RDT, we developed a lateral flow immunoassay (LFIA) for HBsAg utilizing upconverting nanoparticle (UCNP) reporter. The UCNP-LFIA can use whole blood, serum, or plasma and the results can be read in 30 min using a reader device. When compared with a commercial conventional visually read LFIA, the developed UCNP-LFIA had a Limit of Detection (LoD) of 0.1 IU HBsAg/ml in spiked serum, whereas the LoD of the conventional LFIA was 3.2 IU HBsAg/ml. The developed UCNP-LFIA fulfills the WHO criterion for blood screening (LoD ≤ 0.13 IU HBsAg/ml) in terms of LoD. The UCNP-LFIA and conventional LFIA were evaluated with well-characterized sample panels. The UCNP-LFIA detected 20/24 HBsAg-positive samples within the HBsAg Performance Panel and 8/10 samples within the Mixed Titer Performance Panel, whereas the conventional LFIA detected 8/24 and 4/10 samples in these panels, respectively. The performance of the assays was further evaluated with HBsAg-positive (n = 108) and HBsAg-negative (n = 315) patient samples. In comparison with a central laboratory test, UCNP-LFIA showed 95.4% (95% CI: 89.5–98.5%) sensitivity whereas sensitivity of the conventional LFIA was 87.7% (95%CI: 79.9–93.3%). Supplementary Information The online version contains supplementary material available at 10.1007/s00216-020-03055-z. |
Databáze: | OpenAIRE |
Externí odkaz: |